Mitchell Dowsett

Mitchell Dowsett

UNVERIFIED PROFILE

Are you Mitchell Dowsett?   Register this Author

Register author
Mitchell Dowsett

Mitchell Dowsett

Publications by authors named "Mitchell Dowsett"

Are you Mitchell Dowsett?   Register this Author

44Publications

1275Reads

12Profile Views

In Reply.

Arch Pathol Lab Med 2019 04 3;143(4):413-414. Epub 2019 Jan 3.

6   The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0906-LEDOI Listing
April 2019

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Arch Pathol Lab Med 2018 11 30;142(11):1364-1382. Epub 2018 May 30.

Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-090
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0902-SADOI Listing
November 2018

Reply to C. Murray et al and V. Martin et al.

J Clin Oncol 2018 Oct 22:JCO1801163. Epub 2018 Oct 22.

Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford, CA; Brittany E. Harvey, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; and Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01163DOI Listing
October 2018

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

J Clin Oncol 2018 07 30;36(20):2105-2122. Epub 2018 May 30.

Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.77.8738
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.77.8738DOI Listing
July 2018

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.

J Oncol Pract 2018 07 19;14(7):437-441. Epub 2018 Jun 19.

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Stanford University School of Medicine, Stanford, CA; American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00206DOI Listing
July 2018

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.

J Natl Cancer Inst 2018 02;110(2)

Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK; Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK; The Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, UK; Cellular Pathology, Guy's and St Thomas' NHS Trust, Westminster Bridge Rd, London, UK; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article/110/2/166/4064177
Publisher Site
http://dx.doi.org/10.1093/jnci/djx137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298573PMC
February 2018

SNPs for breast cancer risk assessment.

Oncotarget 2017 Nov 3;8(59):99211-99212. Epub 2017 Nov 3.

Jack Cuzick: Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725081PMC
November 2017

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

J Clin Oncol 2017 Apr 3;35(10):1061-1069. Epub 2017 Jan 3.

Matthew J. Ellis and Chad J. Creighton, Baylor College of Medicine; Gildy Babiera and Kelly Hunt, MD Anderson Cancer Center, Houston; Gary Unzeitig, Doctor's Hospital of Laredo, Laredo; Marilyn Leitch, University of Texas Southwestern Campus, Dallas, TX; Vera J. Suman, Mayo Clinic, Rochester MN; Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Cynthia X. Ma, and D. Craig Allred, Washington University School of Medicine, St Louis; Timothy Pluard, St Lukes Hospital, Kansas City, MO; Michael Barnes, Roche Diagnostics, Mountain View; Laura Esserman, University of California San Francisco, San Francisco, CA; Mitchell Dowsett, Royal Marsden Hospital, London, UK; G. Thomas Budd, Cleveland Clinic; Paula Silverman, Case Western Reserve University, Cleveland OH; Eric Winer, Dana-Farber Cancer Institute, Boston MA; Lisa Carey, University of North Carolina, Chapel Hill; David Ota, Duke University, Durham, NC; Pat Whitworth, Nashville Breast Center, Nashville, TN; J. Michael Guenther, St Elizabeth Medical Center, Edgewood, KY; Zoneddy Dayao, University of New Mexico, Albuquerque, NM; and John A. Olson Jr, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353PMC
April 2017

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

J Clin Oncol 2017 Mar 28;35(7):743-750. Epub 2016 Dec 28.

Jack Cuzick, Adam R. Brentnall, Caroline Reuter, and Ivana Sestak, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London; Corrinne Segal, The Institute of Cancer Research; Corrinne Segal, Simone Detre, Elena Lopez-Knowles, and Mitchell Dowsett, Royal Marsden Hospital; Trevor J. Powles, Cancer Centre London, London; Helen Byers and William G. Newman, University of Manchester and Central Manchester Foundation Trust; and Anthony Howell, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.69.8944
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.69.8944DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455424PMC
March 2017

Intrinsic Subgroups or Individual Biomarkers for Predicting Outcome of Metastatic Breast Cancer?

Authors:
Mitchell Dowsett

JAMA Oncol 2016 Oct;2(10):1269-1271

The Ralph Lauren Breast Centre for Breast Cancer Research, Royal Marsden NHS Trust, London, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0983DOI Listing
October 2016

Early Surrogate Markers of Treatment Activity: Where Are We Now?

J Natl Cancer Inst Monogr 2015 May;2015(51):24-8

Academic Department of Biochemistry, Royal Marsden Hospital, London, UK (MK, MD).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv002DOI Listing
May 2015

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

J Natl Cancer Inst Monogr 2015 May;2015(51):90-6

Medical Oncology Unit (VA, ABe), University of Brescia, and Breast Unit (RP, LV, ELS) Spedali Civili Hospital, Brescia, Italy; U.O. Multidisciplinare di Patologia Mammaria, S.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Cremona, Italy (DG, AR, MRC, LD, ABo); Departments of Radiation Oncology (TB) and Pathology (FS), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (MC); Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Milan, Italy (GC); Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine (MGD), and Medical Oncology Unit (SDC), Fondazione IRCCS - Istituto Nazionale Tumori, Milan, Italy (MGD); Academic Department of Biochemistry, Biochemical Endocrinology (MD), Department of Surgery, Breast Unit (PB), and The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and Breast Unit (MD, GS), Royal Marsden Hospital, London, UK; Department of Pathology, Melbourne University, Parkville, Australia (SF); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH); Mount Vernon Cancer Centre, London, UK (AM); Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT (CH); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Division of Medical Oncology, Department of Hemato-oncology, IRCCS Policlinico 'San Matteo' Foundation, Pavia, Italy (PP); Dipartimento Medicina di Laboratorio, SC Anatomia ed Istocitopatologia Diagnostica e di Screening, A.O.U. Città della Salute e della Scienza di Torino, Università di Torino, Turin, Italy (AS); N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia (VS); German Breast Group & University of Frankfurt, Neu-Isenburg, Germany (GvM); The Russell H. Morgan Department of Radiology

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009414PMC
May 2015

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Cell Rep 2014 Feb 23;6(3):514-27. Epub 2014 Jan 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2013.12.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928845PMC
February 2014

The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors.

Cancer Epidemiol Biomarkers Prev 2012 Dec 16;21(12):2167-75. Epub 2012 Oct 16.

Department of Public Heath and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://cebp.aacrjournals.org/cgi/doi/10.1158/1055-9965.EPI-1
Publisher Site
http://dx.doi.org/10.1158/1055-9965.EPI-12-0789DOI Listing
December 2012

Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

Clin Cancer Res 2011 May 15;17(9):3005-12. Epub 2011 Feb 15.

Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1704DOI Listing
May 2011

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

J Clin Pathol 2011 Feb 8;64(2):130-5. Epub 2010 Dec 8.

Academic Department of Biochemistry, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jcp.2010.082966DOI Listing
February 2011

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.

Clin Cancer Res 2010 Aug 3;16(16):4178-87. Epub 2010 Aug 3.

Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0456DOI Listing
August 2010

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

Breast Cancer Res Treat 2010 Jan 27;119(2):315-23. Epub 2009 Feb 27.

Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0329-xDOI Listing
January 2010

Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors.

Cancer Res 2009 Aug;69(16):6490-9

Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, and The Academic Department of Biochemistry, The Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-0280DOI Listing
August 2009

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.

Breast Cancer Res Treat 2009 Jul 1;116(1):53-68. Epub 2008 Jul 1.

Academic Department of Biochemistry, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-008-0081-7DOI Listing
July 2009

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Int J Oncol 2005 Aug;27(2):327-35

Robert H. Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
August 2005

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

Anticancer Res 2002 Jul-Aug;22(4):2317-9

Department of Surgery, South Manchester University Hospital Education and Research Centre, UK.

View Article

Download full-text PDF

Source
September 2002

Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.

Clin Cancer Res 2002 Jul;8(7):2100-8

Breast Unit, Royal Marsden NHS Trust and Institute of Cancer Research, London SW3 6JJ, United Kingdom.

View Article

Download full-text PDF

Source
July 2002